West Pharmaceutical Services Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $493.7M | $492.7M | $593.4M | $585.9M | $661.8M | $346.2M | $241.7M | $206.9M |
| Depreciation & Amortization | $171.4M | $155.4M | $137.3M | $120.6M | $122.3M | $109.1M | $103.4M | $104.4M |
| Depreciation | $168.6M | $151.8M | $133.7M | $116.9M | $116.9M | $104.7M | $100.0M | $101.7M |
| Amortization | $2.8M | $3.6M | $3.6M | $3.7M | $5.4M | $4.4M | $3.4M | $2.7M |
| Stock-Based Compensation | $23.8M | $18.7M | $23.3M | $23.7M | $37.5M | $34.0M | $24.4M | $15.1M |
| Net Cash from Operating Activities | $754.8M | $653.4M | $776.5M | $724.0M | $584.0M | $472.5M | $367.2M | $288.6M |
| Investing Activities | ||||||||
| Capital Expenditures | $285.9M | $377.0M | $362.0M | $284.6M | $253.4M | $174.4M | $126.4M | $104.7M |
| Business Acquisitions | — | — | $0 | $0 | $2.2M | $0 | $18.9M | $0 |
| Net Cash from Investing Activities | $-285.9M | $-378.7M | $-368.7M | $-288.2M | $-253.1M | $-179.5M | $-228.0M | $-100.8M |
| Financing Activities | ||||||||
| Dividends Paid | $61.2M | $59.1M | $57.0M | $54.1M | $51.1M | $48.1M | $45.1M | $42.1M |
| Stock Repurchases | $134.0M | $560.9M | $438.3M | $202.8M | $137.1M | $115.5M | $83.1M | $70.8M |
| Net Cash from Financing Activities | $-185.1M | $-622.6M | $-459.6M | $-293.6M | $-168.1M | $-137.1M | $-36.8M | $-80.7M |
| Net Change in Cash | $306.7M | $-369.3M | $-40.4M | $131.7M | $147.1M | $176.4M | $101.7M | $101.5M |
| Free Cash Flow | $468.9M | $276.4M | $414.5M | $439.4M | $330.6M | $298.1M | $240.8M | $183.9M |